To cite this paper use one of the standards below:
Case presentation: A 67 years old japanese woman presented with a 14-day history of bilateral and painful vision loss. The symptom was first noted at the left eye with right eye involvement within 7 days. Her past medical history was unremarkable, except for an episode of non-complicated lower thoracic herpes zoster infection four weeks prior to the visual disturbance, in which she received adequate treatment with oral acyclovir for 7 days, with full recovery. She had no other neurological symptoms. At our first evaluation, visual acuities were 20/100 OD and 20/200 OS, with red desaturation at OD. There was no RAPD. Fundoscopy revealed bilateral papillary edema. MRI of brain and orbits revealed right anterior and left posterior optic nerve enhancement on T1 fat-suppressed post contrast sequence, suggestive of bilateral optic neuritis. Lumbar puncture showed slightly increased white blood cells with normal glucose and protein levels. After negative infectious/inflammatory and metabolic laboratory testing, she was treated with 5 days of 1g intravenous methylprednisolone followed by 60mg of oral prednisone. Progressive improvement of visual acuity was observed after 2 days of treatment, and full recovery was established by the 5th day. Later, the serum MOG antibodies were found positive. Discussion: Similar to other neuroimmunological disorders, a few reports regarding anti-MOG optic neuritis after infections have been published. Even though cases associated to herpesviridae family are available, this is the first report of bilateral anti-MOG ON following a VZV reactivation. Final comments: Anti-MOG must be considered as a differential diagnosis for patients with bilateral optic neuritis, including elder and oriental descents. To this date, there is no causality relationship between VZV infection and clinical manifestations of MOGAD, however, it should be on the radar of clinicians who face individuals with post infectious neurological symptoms associated with inflammatory demyelinating diseases.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper